Viatris Revenue 2010-2025 | VTRS

Viatris revenue for the twelve months ending March 31, 2025 was $14.330B, a 6.71% decline year-over-year.

  • Viatris annual revenue for 2024 was $14.739B, a 4.46% decline from 2023.
  • Viatris annual revenue for 2023 was $15.427B, a 5.14% decline from 2022.
  • Viatris annual revenue for 2022 was $16.263B, a 9.08% decline from 2021.

Viatris Revenue 2010-2025 | VTRS

  • Viatris annual revenue for 2024 was $14.739B, a 4.46% decline from 2023.
  • Viatris annual revenue for 2023 was $15.427B, a 5.14% decline from 2022.
  • Viatris annual revenue for 2022 was $16.263B, a 9.08% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$147.1B
CVS Health (CVS)$76.8B
Elevance Health (ELV)$65.1B
Cencora (COR)$56.3B
DiDi Global (DIDIY)$25.7B
Labcorp Holdings (LH)$22.2B
Natera (NTRA)$19B
BioMerieux (BMXMF)$17.7B
EUROFINS SCIENT (ERFSF)$15.9B
ICON (ICLR)$15.1B
CochLear (CHEOY)$13.4B
Solventum (SOLV)$12.9B
Medpace Holdings (MEDP)$12.6B
Revvity (RVTY)$12.2B
Avantor (AVTR)$9.7B
Sonic Healthcare (SKHHY)$9.1B
Charles River Laboratories (CRL)$8.7B
HealthEquity (HQY)$8.3B
Caris Life Sciences,�Inc (CAI)$7.5B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$5.1B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.5B
Surgery Partners (SGRY)$2.7B
Organon (OGN)$2.7B
Concentras Parent (CON)$2.5B
Alignment Healthcare (ALHC)$2.3B
GeneDx Holdings (WGS)$2.3B
Progyny (PGNY)$2B
GoodRx Holdings (GDRX)$1.8B